Both in Pharmaceuticals
Alumis vs Arbutus Biopharma
Over the past year ALMS returned +84.6% and ABUS returned +5.2%; their daily moves had a correlation of 0.15.
ALMS +84.6% ABUS +5.2%Growth of $1, one year, split-adjusted
| Metric | ALMS | ABUS |
|---|---|---|
| Price | $7.29 | $4.69 |
| Market cap | $943.6M | $929.1M |
| Today | +1.82% | −3.50% |
| 1 month | −67.4% | −7.5% |
| 6 months | −63.9% | +9.1% |
| Year to date | −25.3% | −2.5% |
| 1 year | +80.0% | +6.3% |
| Revenue growth (YoY) | −37.7% | −90.6% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −8557.2% | −512.0% |
| P/E (TTM) | — | 6.1× |
| Price / sales | 127.5× | 5.1× |
| Net cash | $502.3M | $89.5M |
| Dividend yield | — | — |
| Volatility (60d) | 182.3% | 38.9% |
| Short % of float | 8.5% | 11.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).